Potential therapeutic effect of glycogen synthase kinase 3β inhibition against human glioblastoma

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 887-897

  Miyashita, Katsuyoshi ^a   Kawakami, Kazuyuki ^a   Nakada, Mitsutoshi ^a   Mai, Wei ^a   Shakoori, Abbas ^a,b   Fujisawa, Hironori ^a,c   Hayashi, Yutaka ^a   Hamada, Junichiro ^a   Minamoto, Toshinari ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Fukui Prefectural Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AR A 014418; CYCLIN DEPENDENT KINASE 6; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; NIMUSTINE; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TEMOZOLOMIDE; TYROSINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE;

APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; RADIATION-SENSITIZING AGENTS; RNA INTERFERENCE; THIAZOLES; UREA;

EID: 61349146623     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0760     Document Type: Article

References (50)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344: 114-23.
2. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasison cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411 -22.
3. Stewart LA, Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-8.
4. Diehl KM, Keller ET, Ignatoski KM. Why should we still care about oncogenes? Mol CancerTher 2007;6:418-27.
5. Fischer OM, Streit S, Hart S, Ullrich A. Beyond herceptin and gleevec. Curr Opin Chem Biol 2003;7:490-5.
6. Smith JS,Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246 -56.
7. Pietras K, Sjöblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439 -43.
8. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353: 2012-24. Erratum in: N Engl J Med 2006;354:884.
9. Wen PY,Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006;12:4899-907.
10. Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol CancerTher 2007;6:1909-19.
11. Jope RS,Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007;32:577-95.
12. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
13. Cohen P. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos Trans R Soc Lond B Biol Sci 1999;354:485 -95.
14. Bhat RV, Budd SL. GSK3β signaling: casting a wide net in Alzheimer disease. Neurosignals 2002;11:251 -61.
15. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004;3:479 -87.
16. Meijer L, Flajolet M, Greengard P. Phamacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004;25:471-80.
17. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004;89:1313 -7.
18. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 2002;84:203-29.
19. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement of glycogen synthase kinase-3β in cell survival and NF-κBactivation. Nature 2000;406:86 -90.
20. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005;334:1365-73.
21. Shakoori A, Mai W, Miyashita K, et al. Inhibition of GSK-3β activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007;98:1388-93.
22. Mai W, Miyashita K, Shakoori A, et al. Detection of active fraction of GSK3β in cancer cells by nonradioisotopic in vitro kinase assay. Oncology 2006;71:297 -305.
23. Bhat RV, Shanley J, Correll MP, et al. Regulation and localization of tyrosine 216 phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 2000;97:11074-9.
24. Chin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3β is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 2005;137:193-201.
25. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic β-catenin and MMP-7 (matrilysin) cosegregate in late-stage colon cancer. Gastroenterology 2002;122:60-71.
26. Bhat R, Xue Y, Berg S, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937 -45.
27. Mohri M, Nitta H, YamashitaJ. Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neurooncol 2000;49:105-15.
28. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.
29. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase- 3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076 -81.
30. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, inducesp53-dependentand p53-independentglioma cell death. Oncogene 2003;22:8233 -45.
31. Kulikov R, Boehme KA, Blattner C. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 2005;25:7170-80.
32. Classon M, Harlow E. The retinoblastoma tumor suppressor in development and cancer. Nat Rev Cancer 2002;2:910-7.
33. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase- 3β positively regulates the proliferation of human ovarian cancer cells. Cell Res 2006;16:671 -7.
34. Yao KC, Komata T, Kondo Y, Kanzawa T, Kondo S, Germano IM. Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg 2003;98:378-84.
35. Smalley KS, Contractor R, Haass NK, et al. An organometallic kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 2007;67:209 -17.
36. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Inactivation of glycogen synthase kinase-3β,a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol CancerTher 2007;6:1151 -8.
37. Ghosh JC, Altieri DC. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3β in colorectal cancer cells. Clin Cancer Res 2005;11:4580-8.
38. Lam PY, Di Tomaso E, Ng HK, Pang JC, Roussel MF, Hjelm NM. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 2000;14:28-32.
39. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
40. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
41. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431 -6.
42. Kasuga C, Ebata T, Kayagaki N, et al. Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-κB inhibitors. Cancer Sci 2004;95:840-4.
43. Liao X, Zhang L,ThrasherJB, Du J, Li B. Glycogen synthase kinase-3β suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003;2:1215-22.
44. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997 -1003.
45. Natsume A, Ishii D, Wakabayashi T, et al. IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 2005;65:7573 -9.
46. 366. Biochem J 2007;405:439-44.
47. Mayo LD, Dixon JE, Durden DL,Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277:5484-9.
48. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
49. Raju U, Ariga H, Koto M, et al. Improvement of esophageal adenocarcinoma cell and xenograft response to radiation by targeting cyclin-dependent kinases. Radiother Oncol 2006;80:185-91.
50. 2a L, Burgan WE, Carter DJ, et al. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther 2006;5:1504-10.